

(19) World Intellectual Property Organization  
International Bureau(43) International Publication Date  
14 July 2005 (14.07.2005)

PCT

(10) International Publication Number  
WO 2005/063218 A3(51) International Patent Classification<sup>7</sup>: A61K 9/48, (74) Agent: GRUBB, Philip; Novartis AG, Corporate Intellectual Property, CH-4002 Basel (CH).

(21) International Application Number: PCT/EP2004/014645

(22) International Filing Date: 22 December 2004 (22.12.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data: 60/532,334 23 December 2003 (23.12.2003) US

(71) Applicant (for all designated States except AT, US): NOVARTIS AG [CH/CH]; Lichtstrasse 35, CH-4056 Basel (CH).

(71) Applicant (for AT only): NOVARTIS PHARMA GMBH [AT/AT]; Brunner Strasse 59, A-1230 Vienna (AT).

(72) Inventors; and

(75) Inventors/Applicants (for US only): ZANNOU, Erika, Aina [FR/US]; 303 Timber Oaks Road, Edison, NJ 08820 (US). BATEMAN, Simon, David [GB/US]; 4 Fannington Lane, Randolph, NJ 07869 (US). PUDIPEDDI, Madhusudhan [IN/US]; 51 Calvert Avenue East, Edison, NJ 08826 (US). ROYCE, Alan, Edward [US/US]; RR 4 Box 9LE, Saylorburg, PA 18353 (US). SERAJUDDIN, Abu, T., M. [US/US]; 172-11 35 Avenue, Flushing, Queens, NY 11358 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

**Published:**

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

(88) Date of publication of the international search report:

20 April 2006

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: PHARMACEUTICAL FORMULATIONS OF BISPHOSPHONATES

(57) Abstract: A pharmaceutical formulation comprising an oral dosage form containing a bisphosphonic acid or a salt thereof and an inactive ingredient selected from: an ester of a medium chain fatty acid, or a lipophilic polyethylene glycol ester, said inactive ingredient having a hydrophilic lipophilic balance (HLB) of from about 1 to about 30.